Page last updated: 2024-09-04

moxifloxacin and gdc 0449

moxifloxacin has been researched along with gdc 0449 in 1 studies

Compound Research Comparison

Studies
(moxifloxacin)
Trials
(moxifloxacin)
Recent Studies (post-2010)
(moxifloxacin)
Studies
(gdc 0449)
Trials
(gdc 0449)
Recent Studies (post-2010) (gdc 0449)
3,1575521,69066668611

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)gdc 0449 (IC50)
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.02
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.02
Smoothened homologMus musculus (house mouse)0.07
Sonic hedgehog proteinHomo sapiens (human)0.8825
Sonic hedgehog proteinMus musculus (house mouse)0.0077
Smoothened homologHomo sapiens (human)0.0222
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.4

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ayache, JA; Chang, I; Dresser, MJ; Dufek, MB; Ezzet, F; Graham, RA; Jin, JY; Low, JA; Wang, B; Zerivitz, K1

Trials

1 trial(s) available for moxifloxacin and gdc 0449

ArticleYear
Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
    Journal of cardiovascular pharmacology, 2013, Volume: 61, Issue:1

    Topics: Administration, Oral; Aged; Anilides; Antineoplastic Agents; Aza Compounds; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Fluoroquinolones; France; Heart Rate; Humans; Linear Models; Long QT Syndrome; Middle Aged; Models, Biological; Moxifloxacin; Pyridines; Quinolines; Risk Assessment; Time Factors

2013